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Aims: The present study was to investigate the role of calpain in reactive oxygen species (ROS) production in
endothelial cells and endothelium-dependent vascular dysfunction under experimental conditions of diabetes.
Methods and results: Exposure to high glucose activated calpain, induced apoptosis and reduced nitric oxide
(NO) production without changing eNOS protein expression, its phosphorylation and dimers formation in primary
human umbilical vein endothelial cells (HUVECs). These effects of high glucose correlated with intracellular ROS
production and mitochondrial superoxide generation. Selectively scavenging mitochondrial superoxide increased
NO production in high glucose-stimulated HUVECs. Inhibition of calpain using over-expression of calpastatin or
pharmacological calpain inhibitor prevented high glucose-induced ROS production, mitochondrial superoxide
generation and apoptosis, which were concurrent with an elevation of NO production in HUVECs. In mouse models
of streptozotocin-induced type-1 diabetes and OVE26 type-1 diabetic mice, calpain activation correlated with an
increase in ROS production and peroxynitrite formation in aortas. Transgenic over-expression of calpastatin reduced
ROS production and peroxynitrite formation in diabetic mice. In parallel, diabetes-induced reduction of
endothelium-dependent relaxation in aortic ring was reversed by over-expression of calpastatin in mouse models of
diabetes. However, the protective effect of calpastatin on endothelium-dependent relaxation was abrogated by
eNOS deletion in diabetic mice.
Conclusions: This study suggests that calpain may play a role in vascular endothelial cell ROS production and
endothelium-dependent dysfunction in diabetes. Thus, calpain may be an important therapeutic target to
overcome diabetes-induced vascular dysfunction.
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Diabetes mellitus is one of the worldwide leading causes
of death and long-term disability, resulting in huge social
and economic burden. Vascular abnormalities are the
major contributor to the progression of diabetes and its
associated complications [1]. Because the endothelium is
an important component of vascular homeostasis and
the primary target of hyperglycemia and hyperlipidemia,
endothelial dysfunction occurs in both animal models of* Correspondence: tqpeng@suda.edu.cn
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unless otherwise stated.diabetes and diabetic patients [2-5] and it has been
implicated in diabetic vascular complications [1,2].
Although the pathophysiology of diabetic endothelial
dysfunction is incompletely characterized, it appears to be
multifactorial. Amongst various proposed mechanisms,
oxidative damage induced by reactive oxygen species
(ROS) has been critical in this disorder [6]. Exposure of
endothelial cells to high glucose induces ROS production
in vitro [7,8]. Clinical and animal studies also demonstrate
an increase in vascular ROS formation in diabetes [9,10].
Importantly, treatment with antioxidants improves endo
thelial-dependent vascular relaxation in animal models of
diabetes [11], supporting a central role of ROS in the
development of diabetic endothelial dysfunction. Multiple
mechanisms have been proposed to be responsible for
ROS production in diabetes. In addition to enhancedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the polyol pathway and stimulation of eicosanoid me-
tabolism, ROS is mainly produced by mitochondria,
NADPH oxidase, xanthine oxidase and un-coupled ni-
tric oxide (NO) synthase (NOS) [12-14]. Both xanthine
oxidase and NADPH oxidase have been reported to in-
duce ROS production in diabetic vessels, which signifi-
cantly contributes to endothelial dysfunction [15-17].
Hyperglycemia-induced mitochondrial respiratory chain
deficiencies are postulated to be another critical and
unifying source of ROS generation [15]. Mitochondria-
derived superoxide production may be the initiator for
a vicious cycle of oxidative stress in diabetes [18]. Ex-
cessive ROS production also induces a dysfunctional
eNOS, or referred as eNOS uncoupling, which gener-
ates superoxide instead of NO [3,15]. Increased produc-
tion of superoxide in endothelial cells reacts directly with
NO to form a more harmful molecule peroxynitrite
(ONOOˉ), thereby reducing NO bioavailability [2,3]. Ele-
vated ROS production and reduced NO bioavailability, to-
gether with the intermediate product peroxynitrite,
significantly account for apoptosis in endothelial cells and
endothelial dysfunction in diabetes [19,20]. However, the
regulation of ROS generation has not been fully addressed
in diabetes.
Calpains belong to a family of calcium-dependent thiol-
proteases. They have been involved in a wide variety of
cellular processes including remodeling of cytoskeletal,
caspases activation/apoptosis and acute inflammation
[21]. Two major isoforms of calpain, calpain-1 and
calpain-2, are ubiquitously expressed, and calpastatin is
an endogenous inhibitor for calpain-1 and calpain-2
[21]. Over-expression of calpastatin is shown to inhibit
calpain activity in vitro and in transgenic mice [22].
Calpain activity is increased in endothelial cells under
diabetic conditions [23,24]. An early study showed that
inhibition of calpain increased NO production from
eNOS and reduced leukocyte-endothelium interactions
in microcirculation during hyperglycemia [25]. These
effects of calpain inhibition were further confirmed in a
genetic rat model of type 2 diabetes [24,26]. It has been
also suggested that calpain activation contributes to
microvascular albumin leakage in diabetes [26]. Never-
theless, the role of calpain in diabetic vascular compli-
cations has not been fully characterized. Particularly,
the functional significance of calpain remains to be de-
termined and whether calpain plays a role in regulating
ROS production has never been reported in diabetic
endothelial dysfunction.
In the present study, we employed an in vitro model
of endothelial cells stimulated with high glucose and
multiple in vivo models of diabetes to investigate the
role of calpain in ROS generation and endothelial
dysfunction.Methods
Animals
This investigation conforms to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication, 8th Edition, 2011).
All experimental procedures were approved by the Animal
Use Subcommittee at the University of Western Ontario,
Canada. Breeding pairs of C57BL/6 mice, FVB(Cg)-Tg
(Ins2-CALM)26OveTg(Cryaa-Tag)1Ove/PneJ transgenic
mice (OVE26, a mouse model of type 1 diabetes), db/db
mice (a mouse model of type 2 diabetes), and eNOS
knockout mice (eNOS-KO) were purchased from the
Jackson Laboratory. Transgenic mice over-expressing cal-
pastatin (Tg-CAST) driven by cytomegalovirus promoter
were provided by Dr. Laurent Baud (the Institut National
de la Santé et de la Recherche Médicale, Paris, France)
through the European Mouse Mutant Archive [27].
OVE26/Tg-CAST, eNOS-KO/Tg-CAST and db/db/Tg-
CAST mice were generated by breeding Tg-CAST with
OVE26, eNOS-KO and db/+/− mice, respectively. Type 1
diabetes was induced in adult male mice (10–15 mice in
each group) by intrapenitoneally (i.p.) injection with strep-
tozotocin (STZ, 50 mg/kg/day) for 5 consecutive days as
described in our recent reports [28]. The mice were con-
sidered diabetic and used for the study only if they had
hyperglycemia (>15 mmol/L) at 72 h after the last injec-
tion of STZ, whereas citrate buffer-treated mice were used
as non-diabetic control (blood glucose < 12 mmol/L). Two
months after STZ injection, animals were killed by cer-
vical dislocation with anesthesia (ketamine: 100 mg/kg,
i.p.) and tissues collected for the following analyses.
Cell culture and adenoviral infection
Human umbilical vein endothelial cells (HUVECs) were
isolated from umbilical cord veins and cultured as we
previously described [29]. The isolation of the HUVECs
was performed conforming the declaration of Helsinki
and approved by the ethics review board at the Univer-
sity of Western Ontario. Cells at passage 1–5 were used
in this study.
HUVECs were infected with adenoviral vectors contain-
ing rat calpastatin gene (Ad-CAST, University of Buffalo,
USA) or beta-gal (Ad-gal, Vector Biolabs) as a control at a
multiplicity of infection (MOI) of 10 PFU/cell. Adenovirus-
mediated gene transfer was implemented as previously de-
scribed [30]. All experiments were performed after 24 hours
of adenoviral infection.
Drugs
D-glucose, STZ, phenylephrine (PE), acetylcholine (Ach),
sodium nitroprusside (SNP), mito-TEMPO and calpain
inhibitor-III were purchased from Sigma or Calbiochem.
Hoechst 33324, 2,7- dichlorofluorescein diacetate (DCF-
DA) and dihydroethidium (DHE) were from Invitrogen.
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peptide SS20 which lacks antioxidant properties were syn-
thesized as described previously [31].
Calpain activity
Calpain activity was determined in cell or tissue lysates by
using a fluorescence substrate N-succinyl-LLVY-AMC
(Cedarlane Laboratories) as described previously [28].
ROS production
Intracellular ROS production was detected by using DCF-
DA. Briefly, HUVECs were washed with phosphate-
buffered saline and loaded with freshly prepared DCF-DA
(10 μmol/L) for 15 minutes at 37°C. Hoechst 33324 was
used to stain nucleus. The DCF-DA signals were recorded
by a fluorescence microscope. Aortic tissues were homog-
enized and ROS production was measured in tissue lysates
using DCF-DA and DHE probes as described in our
recent report [30].
Single mitochondrial superoxide generation
Superoxide flashes in single mitochondrion were mea-
sured to determine mitochondrial superoxide generation
in living endothelial cells as described previously [32].
Briefly, HUVECs were infected with an adenoviral vector
expressing mt-cpYFP (Ad-mt-cpYFP). Ad-mt-cpYFP ex-
presses a circularly permuted yellow fluorescent pro-
tein (cpYFP) in the mitochondrial matrix of cells using
the cytochrome C oxidase subunit IV targeting sequence
(mt-cpYFP). Twenty-four hours after infection, confocal
imaging was recorded using the Olympus FV 1000 laser-
scanning microscope equipped with a 63x, 1.3NA oil
immersion objective and a sampling rate of 0.7 s/frame.
The mitochondria-targeted superoxide dismutase analogue
mito-TEMPO was used to confirm superoxide generation
during measurements.
Nitric oxide production
The cell culture media were collected and assayed for NO
production using a commercial kit (Cayman Chemical
Company) according to the manufacturer’s instructions.
Briefly, cell culture medium was harvested and centrifuged
at 1000 g for 2 minutes. Twenty μL of the supernatant of
each sample was incubated with nitrate reductase mix-
ture for 1 hour at room temperature. The NO level was
examined through detection of the fluorescent product
1(H)-naphthotriazole formed from the reaction between
2,3-diaminonaphthalene and nitrite at an excitation wave-
length of 360 nm and an emission wavelength of 430 nm.
Caspase-3 activity
Caspase-3 activity in HUVECs was measured using a
fluorescent assay kit (BIOMOL Research Laboratories)
as described in our previous reports [31].Annexin V staining
HUVECs were incubated with annexin V-conjugated
with FITC and Hoechst 33324 in culture medium as de-
scribed previously [33]. At least 200 cells were examined
from each sample.
Western blot analysis
The protein levels of phosphorylated eNOS (S1179),
eNOS, eNOS dimers and GAPDH were determined by
western blot analysis using specific antibodies against
the corresponding proteins (Cell Signaling), respectively.
Peroxynitrite
The formation of peroxynitrite in the aortas of diabetic
mice was assessed by the immunofluorescent staining
with a primary antibody against nitrotyrosine (Cayman
Chemical Company, dilution 1:100) according to a stand-
ard immunohistofluorescent staining procedure as de-
scribed previously [34].
Relaxation of aortic ring
Mouse aortic ring was prepared and precontracted with
phenylephrine, and endothelium dependent relaxation
was produced by the addition of acetylcholine as described
previously [35,36]. The vaso-relaxations were expressed as
percentage dilation of PE-induced pre-constriction.
Statistical analysis
All data were given as mean ± SD. Differences between
two groups were compared by unpaired Student’s t-test.
For multi-group comparisons, ANOVA followed by
Newman-Keuls test was performed. A two-tailed value
of P < 0.05 was regarded as statistically significant.
Results
Over-expression of calpastatin reduces ROS production in
endothelial cells
In agreement with a previous report [24], we showed that
calpain activity was increased in HUVECs by high glucose
compared with normal glucose (P < 0.05, Figure 1A). High
glucose also significantly induced ROS production in
HUVECs as shown by enhanced DCF-DA fluorescence
(Figure 2A). To investigate the role of calpain in ROS
production, we over-expressed calpastatin in HUVECs by
infection with Ad-CAST and then incubated these cells
with normal (5 mmol/L) or high glucose (30 mmol/L) for
48 hours. Ad-gal was used as a control. Infection of
HUVECS with Ad-CAST significantly decreased calpain
activity (Additional file 1: Figure S1 Effect of calpastatin
over-expression on calpain activity) and the density of
DCF-DA staining following high glucose-stimulation,
indicating that inhibition of calpain prevents ROS produc-
tion (Figure 2A).
Figure 1 Effect of high glucose or diabetes on calpain activity.
(A) Calpain activity in HUVECs incubated with normal glucose (NG,
5 mmol/L) or high glucose (HG, 30 mmol/L) for 48 h. Data are given
as mean ± SD from 3 different experiments. (B) Calpain activity in
the aortas of sham and STZ-induced diabetic mice. (C) Calpain
activity in the aortas of wild-type (WT) and transgenic type 1 diabetic
OVE26 mice. Data are given as mean ± SD, n = 6. * P < 0.05 vs. NG
group, sham mice or WT mice.
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duction under physiological and pathological conditions
[37], we investigated whether calpain plays a role in mito-
chondrial ROS generation. To this end, we measured single
mitochondrion superoxide generation in living endothelialcells. HUVECs were infected with Ad-mpYFP in combin-
ation with Ad-CAST or Ad-gal and then incubated with
normal glucose or high glucose for 24 hours. The mito-
chondrial superoxide flashes were recorded using con-
focal microscope (Figure 2B). High glucose significantly
increased the frequency of mitochondrial superoxide
flashes in HUVECs as compared with normal glucose
(0.0036 vs 0.0018, P < 0.05). In contrast, high glucose-
induced mitochondrial superoxide flashes were reduced
by over-expression of calpastatin (Figure 2C). These
data suggest that calpain activation contributes to mito-
chondrial ROS generation in endothelial cells during
high glucose stimulation.
Inhibition of calpain increases NO production in
endothelial cells by reducing ROS generation
NO production was dramatically decreased in HUVECs
in response to high glucose (P < 0.05, Figure 3A and B).
However, the levels of eNOS protein and phosphorylated
eNOS (Additional file 1: Figure S2 Effects of calpain
inhibition on phosphorylated eNOS in HUVECs), and
the formation of eNOS dimers were not changed during
high glucose incubation (Figure 3C and D). This sug-
gests that the function of eNOS may be not impaired by
high glucose and thus, a reduction in NO production
may be not due to the abnormality of eNOS in high
glucose-stimulated HUVECs. It has been well-known
that NO can be quenched by ROS. Interaction of NO
with superoxide anion leads to the formation of peroxyni-
trite [1,3]. Indeed, inhibition of mitochondrial ROS with a
mitochondrial-targeted antioxidant SS31 increased NO
production in high glucose-stimulated HUVECs in a
dose-dependent manner (Figure 3E). This result argues
that ROS produced by mitochondria accounts for the re-
duction in NO production in endothelial cells during high
glucose stimulation.
Having shown that calpain is important in producing
ROS, we hypothesized that calpain activation reduced
NO production in high glucose-induced HUVECs. In
support of our hypothesis, pharmacological inhibition of
calpain with calpain inhibitor-III or over-expression of
calpastatin significantly increased NO levels in high glu-
cose-stimulated HUVECs (P < 0.05, Figure 3A and B).
However, the protein levels of phosphorylated eNOS were
not changed (Additional file 1: Figure S2 Effects of calpain
inhibition on phosphorylated eNOS in HUVECs).
Apoptosis is attenuated by calpain inhibition
To investigate whether inhibition of calpain would prevent
apoptosis induced by high glucose, we treated HUVECs
with normal glucose or high glucose in the presence of
calpain inhibitor-III (10 μmol/L) or vehicle for 48 hours.
Consistent with previous reports [8,20], high glucose re-
sulted in apoptosis in HUVECs as determined by caspase-
Figure 2 Measurement of ROS production in HUVECs. HUVECs were incubated with normal glucose (NG, 5 mmol/L) or high glucose (HG,
30 mmol/L) in combination with infection with Ad-gal (adenoviral vectors containing beta-gal as a control) or Ad-CAST for 48 h. (A) ROS formation in
HUVECs was determined by DCF-DA staining and the nucleus was identified by Hoechst33342 staining. Representative fluorescent pictures of
Hoechst33342 (blue signal) and DCF-DA staining (green signal) are shown from 3 different experiments. (B, C) Mitochondrial superoxide flashes were
measured in HUVECs. Representative confocal images for the time-course of superoxide flash occurrence from at least 5 cells per experiment in each
group. Arrow indicates superoxide flash in a single mitochondrion (B). Quantification of superoxide flashes per μm2 in every 60 seconds (C). Data are
given as mean ± SD from 4 different experiments. *P < 0.05 vs. NG treated with vehicle or infected with Ad-gal. #P < 0.05 vs. HG treated with vehicle or
infected with Ad-gal.
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bitor-III remarkably decreased apoptosis in high glucose-
stimulated HUVECs (Figure 4A, C and D). Similarly, over-
expression of calpastatin significantly inhibited apoptosis
induced by high glucose (Figure 4B, E and F). These data
demonstrate that inhibition of calpain attenuates high
glucose-induced apoptosis in endothelial cells.
Over-expression of calpastatin reduces ROS production
and peroxynitrite in aortic tissues from diabetic mice
Calpain activity in aortas of STZ-induced diabetic mice
and type-1 diabetic OVE26 mice was increased about2 folds compared to the non-diabetic mice (P < 0.05,
Figure 1B and C). To determine whether calpain con-
tributes to ROS production in vascular tissues from
diabetic mice in vivo, ROS formation was measured
in aortas of wild-type, OVE26 and double transgenic
OVE26/Tg-CAST mice. Compared to wild-type mice,
ROS production in diabetic OVE26 mouse aortas was
significantly increased. Over-expression of calpastatin
significantly decreased ROS production in the vessels of
OVE26/Tg-CAST mice. These results suggest that calpain
activation plays a role in vascular ROS production in vivo
(Figure 5A and B).
Figure 3 Measurement of nitric oxide production and eNOS protein in HUVECs. (A, B) Effects of calpain inhibition on nitric oxide
production. HUVECs were incubated with normal glucose (NG, 5 mmol/L) or high glucose (HG, 30 mmol/L) in combination with calpain inhibitor-III
(CI-III, 10 μmol/L) or infection with Ad-CAST for 48 h. NO production was measured in culture medium. Data are given as mean ± SD from at least 3
different experiments. *P < 0.05 vs. NG treated with vehicle or infected with Ad-gal. #P < 0.05 vs. HG treated with vehicle or infected with Ad-gal.
(C, D) Effect of high glucose on eNOS. HUVECs were incubated with NG or HG for 48 h. The protein levels of eNOS (C), and eNOS monomer and
dimmer were determined (D). (C, D) are representative western blots for eNOS and dimmer formation from 3 different experiments. (E) Nitric oxide
(NO) productions. HUVECs were incubated with high glucose in the presence of mitochondria-targeted antioxidant peptide SS31 (5 or 10 μmol/L) or
control peptide SS20 (10 μmol/L) for 48 h. NO production was measured in culture medium. Data are given as mean ± SD from 3 different experiments.
*P< 0.05 vs. SS20.
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form peroxynitrite [2], we determined the formation of per-
oxynitrite in diabetic mouse aortas. As shown in Figure 5C,
STZ-induced and OVE26 mice displayed a significant
formation of peroxynitrite in aortic endothelium com-
pared to the vessels of non-diabetic controls, confirm-
ing an activated status of nitrated tyrosine in diabetic
vessels [9]. Over-expression of calpastatin inhibited thevascular peroxynitrite formation, supporting an import-
ant role of calpain activity in nitro-oxidative stress in
diabetic vasculature.
Over-expression of calpastatin improves nitric oxide-
dependent vascular relaxation in diabetic mice
Endothelium-dependent vaso-relaxation represents a fun-
damental parameter for the function of endothelium in
Figure 4 Effect of calpain inhibition on apoptosis in high glucose-stimulated HUVECs. HUVECs were incubated with normal glucose
(NG, 5 mmol/L) or high glucose (HG, 30 mmol/L) in combination with calpain inhibitor-III (CI-III, 10 μmol/L) or infection with Ad-CAST for 48 h.
(A, B) Caspase-3 activity. (C, E) Representative images for annexin V staining in HUVECs (Green). (D, F) Quantification of annexin V staining
positive cells. Data are given as mean ± SD from 3 different experiments. * P < 0.05 vs. NG treated with vehicle or infected with Ad-gal. #P < 0.05
vs. HG treated with vehicle or infected with Ad-gal.
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observed in both diabetic patients and animal models
[9-11]. Consistently, our results showed that the relax-
ation in response to Ach was markedly blunted by more
than 50% in aortic rings of STZ-induced diabetic mice
compared with sham animals (P < 0.05, Figure 6A). In
contrast, the vasodilatory function of vascular smooth
muscle assessed by the response to SNP remained com-
parable between diabetic and non-diabetic aortic rings
(Figure 6D). These results indicate that endothelium-
dependent relaxation but not endothelium-independent
vascular function is compromised in our models of dia-
betes, suggesting that the bioavailability of endothelium-
derived NO is reduced in diabetes. However, transgenic
over-expression calpastatin significantly improved thevascular relaxation in STZ-induced Type-1 diabetic
mice (P < 0.05, Figure 6A). To further address the role
of calpain in endothelial dysfunction, we evaluated
endothelium-dependent relaxation in aortic rings from
OVE26 mice. Consistently, the cumulative concentration-
response of aortic rings to Ach was significantly decreased
in OVE26 mice compared with their non-diabetic litter-
mates. Transgenic over-expression of calpastatin re-
stored the vascular relaxation back to the normal levels
(Figure 6B). Similarly, the protective effect of calpasta-
tin over-expression on endothelial function was also
observed in a mouse model of type-2 diabetes, db/db
mice (data not shown). Taken together, over-expression
of calpastatin reduces endothelium-dependent dysfunc-
tion in diabetes.
Figure 5 Effect of calpain inhibition on the ROS production and peroxynitrite formation in the aortas of diabetic mice. (A, B) ROS
formation in the vessels assessed by DHE and DCF-DA staining, respectively. (C) Representative images for peroxynitrite formation in aortas from
4 mice in each group. a, WT mice; b, Tg-CAST mice; c, OVE26 mice; d, OVE26/Tg-CAST mice; e, STZ-injected wild-type (WT) mice; f, STZ-injected
Tg-CAST mice; Data are given as mean ± SD, n = 6. *P < 0.05 vs. WT mice. # P < 0.05 vs. OVE26 mice.
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endothelium-dependent relaxation in diabetic mice
To investigate whether the functional improvement by cal-
pain inhibition was mediated through eNOS-derived NO
pathway, we induced diabetes in eNOS-KO and eNOS-
KO/Tg-CAST mice by STZ injection. Two months after
STZ injection, the blood glucose levels and blood pressure
were comparable between eNOS-KO and eNOS-KO/
Tg-CAST mice (data not shown). We then evaluated the
vascular function by measuring endothelium-dependent
relaxation. Our results showed that the response of aorticrings to Ach was almost abolished in eNOS-KO mice while
the response to SNP remained unchanged (Figure 6C and
F). Over-expression of calpastatin did not improve this re-
sponse in diabetic eNOS-KO/Tg-CAST mice. These find-
ings further confirm that the eNOS/NO pathway but not
other vasodilatory factors are involved in calpain-mediated
endothelial dysfunction during diabetes.
Discussion
The current study investigated the role of calpain in
endothelial ROS production and endothelial dysfunction
Figure 6 Role of calpain in endothelium-dependent and -independent relaxation. Aortic rings were pre-contracted by phenylephrine and
the subsequent responses to acetylcholine (Ach) or sodium nitroprusside (SNP) were recorded. (A-C) the response to Ach in STZ-induced mice
(A), OVE26 mice (B), and eNOS knockout mice (C) (D-F). the response to SNP in STZ-induced mice (D), OVE26 mice (E), and eNOS knockout mice
(F). Data are given as mean ± SD, n = 6-8. *P < 0.05.
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time that inhibition of calpain reduces mitochondrial
superoxide generation, intracellular ROS production and
apoptotic cell death in high glucose-stimulated endothelial
cells. The effects of calpain inhibition correlate with an
elevation of NO production and selectively scavenging
mitochondrial ROS increases NO production during high
glucose stimulation. In mouse models of type-1 and
type-2 diabetes, transgenic over-expression of calpasta-
tin reduces vascular ROS production, inhibits peroxyni-
trite formation, and attenuates the dysfunction of
endothelium-dependent relaxation. Thus, this study re-
veals a novel role of calpain activation in endothelial
ROS generation under diabetic conditions. Excessive
ROS possibly produced by mitochondria quenches NO,
thereby generating toxic oxidant species peroxynitriteand reducing NO bio-availability and thus, induces
endothelial dysfunction in diabetes.
Studies have demonstrated that high glucose or diabetes
increases cytosolic Ca2+ concentration and thus induces
calpain activation in cultured endothelial cells and in
micro/macro-vascular tissues of type-1 and type-2 diabetes
[23,24,38]. To further confirm these previous findings, the
present study also revealed that calpain activity was mark-
edly increased in HUVECs stimulated with high glucose
and in aortas of both STZ-induced type-1 diabetic mice
and transgenic type-1 diabetic mice (OVE26 mice). The
up-regulation of calpain activity in endothelial cells has
been implicated in vascular inflammation and endothelial
leakage in diabetes [24,26]. The present study provides
additional functional evidence demonstrating that calpain ac-
tivation contributes to endothelium-dependent dysfunction
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models of diabetes including STZ-induced, genetically
modified type-1 and db/db type-2 diabetes were employed.
Endothelium-dependent vasodilation was impaired in all
diabetic mice, confirming previous findings [9-11]. How-
ever, transgenic over-expression of calpastatin rescued the
endothelium-dependent vascular relaxation in response to
Ach in diabetic aortic rings. There was no alteration of
vascular relaxation in response to NO donor SNP in both
diabetic mice and transgenic mice with calpastatin over-
expression as compared to non-diabetic and wild-type
mice, respectively, suggesting that the function of smooth
muscle relaxation in aortic rings of diabetic mice is pre-
served. It has been known that the release of prostacyclin,
in particular PGI2, also induces endothelium-dependent
relaxation in large arteries [39,40]. To exclude the involve-
ment of those NO independent factors in calpain-mediated
dysfunction of endothelium-dependent relaxation, we
demonstrated that deletion of eNOS abrogated the benefi-
cial effect of calpastatin over-expression on endothelium-
dependent relaxation in diabetic aortic rings. Thus, it is
highly possible that the improvement of vascular relax-
ation in response to Ach in diabetic calpastatin transgenic
mice results from an increase in NO bioavailability. It is
worthwhile to mention that a previous study has demon-
strated that the predominant agonist-induced endo
thelium-dependent vasodilation is mediated by endo
thelium-derived hyperpolarizing factor (EDHF), not by
NO in murine resistance vessels [41]. In the small arteries
of diabetic rats, it has been shown that that NO-dependent
vasorelaxation is preserved, whereas EDHF-dependent
response is impaired [42]. Thus, it seems that big arteries
(such as aortas) and small arteries may respond differently
to diabetes in terms of vascular relaxation. Whether
calpastatin over-expression could also improve EDHF-
dependent response in diabetic resistance arteries needs
future investigation for clarification. In addition, calpain
has been shown to positively regulate eNOS activation and
NO production in endothelial cells in response to VEGF
[43], suggesting that the role of calpain in NO production
may be dependent on distinct stimuli.
An important finding is that calpain activation mediates
ROS production in vasculatures of diabetes. Intriguingly,
inhibition of calpain attenuated mitochondrial superoxide
generation in high glucose-stimulated endothelial cells,
suggesting that calpain may play a role in mitochondrial
ROS generation in diabetes. Recent findings suggest that
over-generation of ROS through mitochondrial electron
transport chain contributes to the diabetic vascular injury
[14,18]. Uncoupling protein 2, a critical regulator of
mitochondrial-derived ROS release, has been shown to
attenuate the endothelial dysfunction by increasing NO
bioavailability and inhibiting ROS production in diabetic
mice [14,44]. In addition to the electron transport system,mitochondria also produce ROS through monoamine
oxidase-dependent pathway in diabetes [13]. However, it
is currently unknown how calpain activation contributes
to mitochondrial ROS generation in endothelial cells.
Study has shown that hyperhomocysteinemia induces the
translocation of active calpain-1 from cytosol to mitochon-
dria, leading to increased intramitochondrial oxidative
stress in cultured rat heart microvascular endothelial cells
[45]. In this regard, some important mitochondrial proteins
have been identified as substrates of calpain-1, such as
ATP5A1 [46], optic atrophy-1 [47], apoptosis-inducing fac-
tor [48], etc. Disruption of these mitochondrial proteins
may induce mitochondrial dysfunction and excessive ROS
generation. Nevertheless, further investigations are needed
to determine the mechanisms by which calpain induces
mitochondrial ROS generation in endothelial cells. Since
there may be cross-talks between main ROS sources
(mitochondria, NADPH oxidase, xanthine oxidase or un-
coupled NOS) [49], it is very hard to determine the rela-
tive importance of individual ROS source in diabetes.
There is a general consensus that increased ROS produc-
tion in the vascular wall, particularly within endothelial
cells, contributes largely to the diabetic endothelial injury
[1,2]. In addition to its role in promoting vascular inflam-
mation [50,51], excessive ROS production can induce
apoptotic cell death in endothelial cells [8,20]. In support
of this view, we showed that inhibition of calpain prevented
high glucose-induced apoptosis in endothelial cells. ROS,
in particular superoxide anion reacts very rapidly and
efficiently with NO to generate the extremely detrimental
species peroxynitrite, reducing the bio-availability of NO
production [19]. In this regard, we found that NO produc-
tion was reduced in high glucose-stimulated endothelial
cells and peroxynitrite formation was increased in vascular
walls of diabetic mice. This is also supported by previous
reports [7-9,52]. Importantly, inhibition of calpain elevated
NO production in endothelial cells and attenuated the
formation of peroxynitrite in aortas of diabetic mice. These
data suggest that calpain activation mediates ROS gener-
ation, which in turn quenches NO, and thereby reducing
its bio-availability in endothelial cells during diabetes. It is
important to mention that a reduction in NO production
may also result from eNOS dysfunction [3]. However, the
present study found that incubation with high glucose did
not change the protein levels of eNOS and phosphorylated
eNOS, and the formation of eNOS dimers in endothelial
cells, indicating that calpain may not directly disrupt the
function of eNOS in producing NO. Indeed, previous
reports have demonstrated that diabetes reduced NO bio-
availability without altering eNOS protein and its dimer
formation in endothelial cells [53,54]. Further evidence in
support of our conclusion was that calpain cleaved eNOS
protein without affecting the eNOS activity [43,55]. How-
ever, our current and these previous findings are different
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may induce the disruption of eNOS in producing NO dur-
ing oxidized LDL stimulation [56]. This discrepancy may
be due to different stimuli: hyperglycemia versus oxidized
LDL. Therefore, we conclude that inhibition of calpain
increases NO bio-availability, at least in part, by reducing
ROS formation and improving eNOS function in endothe-
lial cells under pathological conditions.
While the present study investigated the role of calpain
in ROS generation in endothelial dysfunction during dia-
betes, it is important to mention that multiple mechanisms
may be involved in calpain activation-mediated diabetic
vascular complications. Calpain has been shown to target
and cleave IκB, and activate NF-κB signaling, leading to
inflammatory responses and apoptosis in vasculatures of
diabetes [25]. Calpain may also mediate apoptosis in endo-
thelial cells by directly targeting Bid and apoptosis indu-
cible factor [57]. Thus, further studies will be needed to
fully address the role of calpain in diabetic vascular
complications.
In conclusion, we have demonstrated an important role
of calpain in endothelial ROS production during hypergly-
cemia/diabetes, which is associated with apoptosis and a
reduction in NO generation in endothelial cells. Genetic
inhibition of calpain through over-expression of calpasta-
tin reduces vascular ROS production and peroxynitrite
formation, and improves endothelium-dependent relax-
ation in diabetic mice. Given that calpain has been impli-
cated in vascular inflammation [24,25] and endothelial
leakage [26], this study provides further evidence to sup-
port the view that calpain may serve as a potential thera-
peutic target for diabetic cardiovascular complications.Additional file
Additional file 1: Figure S1. Effect of calpastatin over-expression on
calpain activity. HUVECs were infected with Ad-CAST or Ad-gal, and then
incubated with normal glucose (NG, 5mmol/L) or high glucose (HG, 30
mmol/L) for 48 hours. Calpain activity was determined. Data are mean ±
SD from 3 different experiments. *P < 0.05 versus NG+Ad-gal and
#P < 0.05 HG+Ad-CAST. Figure S2. Effects of calpain inhibition on
phosphorylated eNOS in HUVECs. HUVECs were incubated with normal
glucose (NG, 5 mmol/L) or high glucose (HG, 30 mmol/L) in combination
with calpain inhibitor-III (CI-III, 10 μmol/L) or vehicle for 48 hours. (A) A
representative western blot for phosphorylated eNOS from 4 different
experiments. (B) The ratio of phosphorylated eNOS to total eNOS. Data
are mean ± SD, n=4.
Competing interest
The authors declare that they have no competing interest.
Authors’ contributions
BC, FT and IC carried out in vitro studies. QZ measured calpain activity and
ROS formation in aortas. RN measured mitochondrial superoxide generation
in HUVECs. BC and LS assessed vascular relaxation and analyzed the data.
TP designed the study. GC, WW and PS contributed to research materials.
BC, GC, WW, PS and TP wrote the manuscript. All authors read and approved
the final manuscript.Funding
This study was supported by an operating grant from the Canadian Institutes
of Health Research (to TP and PWS), U.S. National Institutes of Health grant
DA-004443 (to PWS), and partly by Soochow University and Western
University Department of Medicine Program of Experimental Medicine
(POEM) Research Award. Dr Peng is a recipient of a New Investigator Award
from the Canadian Institutes of Health Research.
Author details
1Institute for Cardiovascular Science of Soochow University, Suzhou, Jiangsu
Province 215123, China. 2Lawson Health Research Institute, London Health
Sciences Centre, London N6A 4G5, Ontario, Canada. 3Department of
Medicine, University of Western Ontario, London N6A 4G5, Ontario, Canada.
4Department of Pathology, University of Western Ontario, London N6A 4G5,
Ontario, Canada. 5Department of Cardiology, Shanghai 6th People’s Hospital,
Shanghai Jiaotong University School of Medicine, Shanghai 200233, China.
6Mitochondria and Metabolism Center, Departments of Anesthesiology and
Pain Medicine, University of Washington, Seattle, USA. 7Laboratory of
Chemical Biology and Peptide Research, Clinical Research Institute of
Montreal, Montreal, Quebec H2W 1R7, Canada. 8Critical Illness Research,
Lawson Health Research Institute, VRL 6th Floor, A6-140, 800 Commissioners
Road, London, Ontario, Canada.
Received: 20 January 2014 Accepted: 25 April 2014
Published: 3 May 2014References
1. Creager MA, Luscher TF, Cosentino F, Beckman JA: Diabetes and vascular
disease: pathophysiology, clinical consequences, and medical therapy:
Part I. Circulation 2003, 108(12):1527–1532.
2. Xu J, Zou MH: Molecular insights and therapeutic targets for diabetic
endothelial dysfunction. Circulation 2009, 120(13):1266–1286.
3. Triggle CR, Ding H: A review of endothelial dysfunction in diabetes: a
focus on the contribution of a dysfunctional eNOS. J Am Soc Hypertens 2010,
4(3):102–115.
4. Shemyakin A, Kovamees O, Rafnsson A, Bohm F, Svenarud P, Settergren M,
Jung C, Pernow J: Arginase inhibition improves endothelial function in
patients with coronary artery disease and type 2 diabetes mellitus.
Circulation 2012, 126(25):2943–2950.
5. Burlet E, Jain SK: Manganese supplementation reduces high glucose-
induced monocyte adhesion to endothelial cells and endothelial
dysfunction in Zucker diabetic fatty rats. J Biol Chem 2013, 288(9):6409–6416.
6. Pennathur S, Heinecke JW: Oxidative stress and endothelial dysfunction in
vascular disease. Curr Diab Rep 2007, 7(4):257–264.
7. Quijano C, Castro L, Peluffo G, Valez V, Radi R: Enhanced mitochondrial
superoxide in hyperglycemic endothelial cells: direct measurements and
formation of hydrogen peroxide and peroxynitrite. Am J Physiol Heart Circ
Physiol 2007, 293(6):H3404–3414.
8. Cifarelli V, Geng X, Styche A, Lakomy R, Trucco M, Luppi P: C-peptide
reduces high-glucose-induced apoptosis of endothelial cells and
decreases NAD(P)H-oxidase reactive oxygen species generation in
human aortic endothelial cells. Diabetologia 2011, 54(10):2702–2712.
9. Lau YS, Tian XY, Huang Y, Murugan D, Achike FI, Mustafa MR: Boldine protects
endothelial function in hyperglycemia-induced oxidative stress through an
antioxidant mechanism. Biochem Pharmacol 2013, 85(3):367–375.
10. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM:
Mechanisms of increased vascular superoxide production in human
diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide
synthase. Circulation 2002, 105(14):1656–1662.
11. Leo CH, Hart JL, Woodman OL: 3',4'-Dihydroxyflavonol reduces superoxide
and improves nitric oxide function in diabetic rat mesenteric arteries.
PLoS One 2011, 6(6):e20813.
12. Fatehi-Hassanabad Z, Chan CB, Furman BL: Reactive oxygen species and
endothelial function in diabetes. Eur J Pharmacol 2010, 636(1–3):8–17.
13. Rochette L, Lorin J, Zeller M, Guilland JC, Lorgis L, Cottin Y, Vergely C: Nitric
oxide synthase inhibition and oxidative stress in cardiovascular diseases:
possible therapeutic targets? Pharmacol Ther 2013, 140(3):239–257.
14. Sun J, Pu Y, Wang P, Chen S, Zhao Y, Liu C, Shang Q, Zhu Z, Liu D:
TRPV1-mediated UCP2 upregulation ameliorates hyperglycemia-induced
endothelial dysfunction. Cardiovasc Diabetol 2013, 12:69.
Chen et al. Cardiovascular Diabetology 2014, 13:88 Page 12 of 12
http://www.cardiab.com/content/13/1/8815. Giacco F, Brownlee M: Oxidative stress and diabetic complications.
Circ Res 2010, 107(9):1058–1070.
16. Dikalov S: Cross talk between mitochondria and NADPH oxidases.
Free Radic Biol Med 2011, 51(7):1289–1301.
17. Bravard A, Bonnard C, Durand A, Chauvin MA, Favier R, Vidal H, Rieusset J:
Inhibition of xanthine oxidase reduces hyperglycemia-induced oxidative
stress and improves mitochondrial alterations in skeletal muscle of
diabetic mice. Am J Physiol Endocrinol Metab 2011, 300(3):E581–591.
18. Brownlee M: Biochemistry and molecular cell biology of diabetic
complications. Nature 2001, 414(6865):813–820.
19. Johansen JS, Harris AK, Rychly DJ, Ergul A: Oxidative stress and the use of
antioxidants in diabetes: linking basic science to clinical practice.
Cardiovasc Diabetol 2005, 4(1):5.
20. Ho FM, Lin WW, Chen BC, Chao CM, Yang CR, Lin LY, Lai CC, Liu SH, Liau CS:
High glucose-induced apoptosis in human vascular endothelial cells is
mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and
prevented by PI3K/Akt/eNOS pathway. Cell Signal 2006, 18(3):391–399.
21. Goll DE, Thompson VF, Li H, Wei W, Cong J: The calpain system. Physiol Rev 2003,
83(3):731–801.
22. Letavernier E, Perez J, Bellocq A, Mesnard L, de Castro KA, Haymann JP, Baud L:
Targeting the calpain/calpastatin system as a new strategy to prevent
cardiovascular remodeling in angiotensin II-induced hypertension. Circ Res 2008,
102(6):720–728.
23. Wang S, Peng Q, Zhang J, Liu L: Na+/H + exchanger is required for
hyperglycaemia-induced endothelial dysfunction via calcium-dependent
calpain. Cardiovasc Res 2008, 80(2):255–262.
24. Stalker TJ, Gong Y, Scalia R: The calcium-dependent protease calpain causes
endothelial dysfunction in type 2 diabetes. Diabetes 2005, 54(4):1132–1140.
25. Stalker TJ, Skvarka CB, Scalia R: A novel role for calpains in the endothelial
dysfunction of hyperglycemia. FASEB J 2003, 17(11):1511–1513.
26. Scalia R, Gong Y, Berzins B, Zhao LJ, Sharma K: Hyperglycemia is a major
determinant of albumin permeability in diabetic microcirculation: the
role of mu-calpain. Diabetes 2007, 56(7):1842–1849.
27. Peltier J, Bellocq A, Perez J, Doublier S, Dubois YC, Haymann JP, Camussi G,
Baud L: Calpain activation and secretion promote glomerular injury in
experimental glomerulonephritis: evidence from calpastatin-transgenic
mice. J Am Soc Nephrol 2006, 17(12):3415–3423.
28. Li Y, Ma J, Zhu H, Singh M, Hill D, Greer PA, Arnold JM, Abel ED, Peng T:
Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis
in mouse models of type 1 diabetes. Diabetes 2011, 60(11):2985–2994.
29. Cepinskas G, Sandig M, Kvietys PR: PAF-induced elastase-dependent
neutrophil transendothelial migration is associated with the mobilization
of elastase to the neutrophil surface and localization to the migrating
front. J Cell Sci 1999, 112(Pt 12):1937–1945.
30. Ma J, Wang Y, Zheng D, Wei M, Xu H, Peng T: Rac1 signalling mediates
doxorubicin-induced cardiotoxicity through both reactive oxygen species-
dependent and -independent pathways. Cardiovasc Res 2013, 97(1):77–87.
31. Zhu H, Yang Y, Wang Y, Li J, Schiller PW, Peng T: MicroRNA-195 promotes
palmitate-induced apoptosis in cardiomyocytes by down-regulating
Sirt1. Cardiovasc Res 2011, 92(1):75–84.
32. Wang W, Fang H, Groom L, Cheng A, Zhang W, Liu J, Wang X, Li K, Han P,
Zheng M, Yin J, Mattson MP, Kao JP, Lakatta EG, Sheu SS, Ouyang K, Chen J,
Dirksen RT, Cheng H: Superoxide flashes in single mitochondria. Cell 2008,
134(2):279–290.
33. Wang Y, Zheng D, Wei M, Ma J, Yu Y, Chen R, Lacefield JC, Xu H, Peng T:
Over-expression of calpastatin aggravates cardiotoxicity induced by
doxorubicin. Cardiovasc Res 2013, 98(3):381–390.
34. Vattemi G, Mechref Y, Marini M, Tonin P, Minuz P, Grigoli L, Guglielmi V,
Klouckova I, Chiamulera C, Meneguzzi A, Di Chio M, Tedesco V, Lovato L,
Degan M, Arcaro G, Lechi A, Novotny MV, Tomelleri G: Increased protein
nitration in mitochondrial diseases: evidence for vessel wall
involvement. Mol Cell Proteomics 2011, 10(4):M110 002964.
35. Schuh K, Quaschning T, Knauer S, Hu K, Kocak S, Roethlein N, Neyses L:
Regulation of vascular tone in animals overexpressing the sarcolemmal
calcium pump. J Biol Chem 2003, 278(42):41246–41252.
36. Ansari HR, Nadeem A, Talukder MA, Sakhalkar S, Mustafa SJ:
Evidence for the involvement of nitric oxide in A2B receptor-mediated
vasorelaxation of mouse aorta. Am J Physiol Heart Circ Physiol 2007, 292(1):
H719–725.
37. Balaban RS, Nemoto S, Finkel T: Mitochondria, oxidants, and aging. Cell
2005, 120(4):483–495.38. Ohara T, Sussman KE, Draznin B: Effect of diabetes on cytosolic free Ca2+
and Na(+)-K(+)-ATPase in rat aorta. Diabetes 1991, 40(11):1560–1563.
39. Williams SP, Dorn GW 2nd, Rapoport RM: Prostaglandin I2 mediates
contraction and relaxation of vascular smooth muscle. Am J Physiol 1994,
267(2 Pt 2):H796–803.
40. Jones RL, Chan K: Distinction between relaxations induced via prostanoid
EP(4) and IP(1) receptors in pig and rabbit blood vessels. Br J Pharmacol 2001,
134(2):313–324.
41. Brandes RP, Schmitz-Winnenthal FH, Feletou M, Godecke A, Huang PL,
Vanhoutte PM, Fleming I, Busse R: An endothelium-derived hyperpolarizing
factor distinct from NO and prostacyclin is a major endothelium-dependent
vasodilator in resistance vessels of wild-type and endothelial NO synthase
knockout mice. Proc Natl Acad Sci U S A 2000, 97(17):9747–9752.
42. Wigg SJ, Tare M, Tonta MA, O'Brien RC, Meredith IT, Parkington HC: Comparison
of effects of diabetes mellitus on an EDHF-dependent and an EDHF-
independent artery. Am J Physiol Heart Circ Physiol 2001, 281(1):H232–240.
43. Youn JY, Wang T, Cai H: An ezrin/calpain/PI3K/AMPK/eNOSs1179 signaling
cascade mediating VEGF-dependent endothelial nitric oxide production.
Circ Res 2009, 104(1):50–59.
44. Tian XY, Wong WT, Xu A, Lu Y, Zhang Y, Wang L, Cheang WS, Wang Y, Yao X,
Huang Y: Uncoupling protein-2 protects endothelial function in diet-induced
obese mice. Circ Res 2012, 110(9):1211–1216.
45. Moshal KS, Singh M, Sen U, Rosenberger DS, Henderson B, Tyagi N, Zhang H,
Tyagi SC: Homocysteine-mediated activation and mitochondrial translocation
of calpain regulates MMP-9 in MVEC. Am J Physiol Heart Circ Physiol 2006,
291(6):H2825–2835.
46. Brule C, Dargelos E, Diallo R, Listrat A, Bechet D, Cottin P, Poussard S:
Proteomic study of calpain interacting proteins during skeletal muscle
aging. Biochimie 2010, 92(12):1923–1933.
47. Jahani-Asl A, Pilon-Larose K, Xu W, MacLaurin JG, Park DS, McBride HM, Slack RS:
The mitochondrial inner membrane GTPase, optic atrophy 1 (Opa1), restores
mitochondrial morphology and promotes neuronal survival following
excitotoxicity. J Biol Chem 2011, 286(6):4772–4782.
48. Ozaki T, Yamashita T, Ishiguro S: Mitochondrial m-calpain plays a role in the
release of truncated apoptosis-inducing factor from the mitochondria.
Biochim Biophys Acta 2009, 1793(12):1848–1859.
49. Shen E, Li Y, Shan L, Zhu H, Feng Q, Arnold JM, Peng T: Rac1 is required for
cardiomyocyte apoptosis during hyperglycemia. Diabetes 2009, 58(10):2386–2395.
50. Gabunia K, Ellison SP, Singh H, Datta P, Kelemen SE, Rizzo V, Autieri MV:
Interleukin-19 (IL-19) induces heme oxygenase-1 (HO-1) expression and
decreases reactive oxygen species in human vascular smooth muscle
cells. J Biol Chem 2012, 287(4):2477–2484.
51. Bryk D, Zapolska-Downar D, Malecki M, Hajdukiewicz K, Sitkiewicz D: Trans
fatty acids induce a proinflammatory response in endothelial cells
through ROS-dependent nuclear factor-kappaB activation. J Physiol
Pharmacol 2011, 62(2):229–238.
52. Aljofan M, Ding H: High glucose increases expression of cyclooxygenase-2,
increases oxidative stress and decreases the generation of nitric oxide in
mouse microvessel endothelial cells. J Cell Physiol 2010, 222(3):669–675.
53. Weidig P, McMaster D, Bayraktutan U: High glucose mediates pro-oxidant
and antioxidant enzyme activities in coronary endothelial cells.
Diab Obes Metab 2004, 6(6):432–441.
54. Salt IP, Morrow VA, Brandie FM, Connell JM, Petrie JR: High glucose inhibits
insulin-stimulated nitric oxide production without reducing endothelial
nitric-oxide synthase Ser1177 phosphorylation in human aortic endothelial
cells. J Biol Chem 2003, 278(21):18791–18797.
55. Averna M, Stifanese R, De Tullio R, Salamino F, Bertuccio M, Pontremoli S, Melloni E:
Proteolytic degradation of nitric oxide synthase isoforms by calpain is modulated
by the expression levels of HSP90. FEBS J 2007, 274(23):6116–6127.
56. Dong Y, Wu Y, Wu M, Wang S, Zhang J, Xie Z, Xu J, Song P, Wilson K, Zhao Z,
Lyons T, Zou MH: Activation of protease calpain by oxidized and glycated
LDL increases the degradation of endothelial nitric oxide synthase.
J Cell Mol Med 2009, 13(9A):2899–2910.
57. Vindis C, Elbaz M, Escargueil-Blanc I, Auge N, Heniquez A, Thiers JC, Negre-Salvayre A,
Salvayre R: Two distinct calcium-dependent mitochondrial pathways are involved
in oxidized LDL-induced apoptosis. Arterioscler Thromb Vasc Biol 2005, 25(3):639–645.
doi:10.1186/1475-2840-13-88
Cite this article as: Chen et al.: Inhibition of calpain reduces oxidative
stress and attenuates endothelial dysfunction in diabetes. Cardiovascular
Diabetology 2014 13:88.
